Ozenoxacin
Names | |
---|---|
IUPAC name
1-Cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid | |
Identifiers | |
245765-41-7 | |
3D model (Jmol) | Interactive image |
ChemSpider | 8039521 |
PubChem | 9863827 |
| |
| |
Properties | |
C21H21N3O3 | |
Molar mass | 363.42 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
Ozenoxacin is an experimental quinolone antibiotic being developed for the treatment of impetigo and other dermatological bacterial infections.[1] Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics.[2]
References
- ↑ "Ferrer successfully completes a phase III clinical trial in adult and paediatric patients with impetigo for novel antibacterial compound Ozenoxacin". drugs.com. June 2013.
- ↑ López Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Cantón R, Vila J (Dec 2013). "In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria". Antimicrob Agents Chemother. 57 (12): 6389–6392. doi:10.1128/AAC.01509-13. PMC 3837899. PMID 24080666.
This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.